Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV)-16/18 Vaccine, Cervarix® When Administered to Healthy Females According to the Prescribing Information in Korea

NCT01101542 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01101542
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01101542 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV)-16/18 Vaccine, Cervarix® When Administered to Healthy Females According to the Prescribing Information in Korea
Lead sponsor
GlaxoSmithKline
Phase
Observational
Overall status
Completed
Start date
July 1, 2010
Completion date
February 20, 2014
Enrollment
3,091 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

infections, papillomavirus